Discussions regarding diversity, equity, and inclusion in healthcare and clinical research have been ongoing for decades. However, the COVID-19 global pandemic brought about a new focus on this issue.
There is a common refrain that appears throughout the Reagan-Udall Foundation report on the Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA) — lack of transparency.
April 13, 2023, 2-3 PM ET
It is no secret that the FDA has been under scrutiny for multiple reasons related to the authorization of safer nicotine alternative products. Last Summer the agency was heavily criticised by Senators Dick Durbin (D-Ill.) and Susan Collins (R-Maine).
The failures of the federal Food and Drug Administration (FDA) have been in plain view since at least early 2022.
At that point the public saw the FDA’s scandalous neglect of Abbott Nutrition’s contaminated infant formula — which was reported to it five months before Abbott recalled the product — and Politico’s detailed exposé of the agency’s incompetence, which extends back through several presidential administrations.
